ArticleArchives of Razi Institute2024
Piracetam as Neuroprotective, Anticonvulsant, and Anti-Anxiety Agent: An
Article in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy, a category of neurological disorder, is characterized by recurrent seizures. Epileptic seizures are characterized by sudden alterations in brain electrical activity. Piracetam is a derivative of cyclic aminobutyric acid that exerts neuroprotective effects. The objective of this study was to evaluate the neuroprotective, anticonvulsant, and anti-anxiety effects of piracetam in the pentylenetetrazole (PTZ) seizure rat model. To evaluate the anticonvulsant properties of piracetam in the PTZ seizure model, the experimental groups were administered piracetam at doses of 30 or 100 mg/kg. The positive control group was administered diazepam (2 mg/kg), while the negative control group was treated with only PTZ. The anti-anxiety effects were evaluated using the elevated plus maze and open field tests. Additionally, the antioxidant effects of piracetam on brain tissues were examined. The open field test results demonstrated a significant increase in the number of crossings over the line in the Piracetam (30 and 100 mg/kg) and diazepam groups, in comparison to the negative control group. In the plus maze test, the groups administered Piracetam demonstrated a greater tendency to spend time in the open arms than the control group. Furthermore, diazepam markedly elevated the time spent in the open arms in comparison to the negative control group. The histological results demonstrated structural alterations in hippocampal neurons. Additionally, the antioxidant test demonstrated that Piracetam possesses antioxidant properties when compared to the negative control group. Piracetam demonstrated anticonvulsant and neuroprotective effects in PTZ-induced epileptic rats, exhibiting the ability to inhibit or reduce the incidence of seizures. Additionally, it demonstrated anti-anxiety and sedative properties. The neuroprotective effects of Piracetam may be attributed to its ability to regulate neurotransmitter systems, including cholinergic, serotonergic, noradrenergic, and glutamatergic pathways. It can be posited that Piracetam may possess neuroprotective, anti-epileptic, anti-anxiety, and antioxidant properties in PTZ epileptic rats. Nevertheless, additional research is required to substantiate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.